董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andre Auberton Herve | 男 | Chairman of the Board | 60 | 18.00万美元 | 未持股 | 2022-12-07 |
| Michal Prywata | 男 | Director | 30 | 25.94万美元 | 未持股 | 2022-12-07 |
| Remi Gaston Dreyfus | 男 | Director | 66 | 5.00万美元 | 未持股 | 2022-12-07 |
| Joseph Martin | 男 | Director | 74 | 5.00万美元 | 未持股 | 2022-12-07 |
| Charles Matine | 男 | Director | 63 | 5.00万美元 | 未持股 | 2022-12-07 |
| Audrey Thevenon | 女 | Director | 44 | 5.00万美元 | 未持股 | 2022-12-07 |
| Rich Russo, Jr. | 男 | Chief Executive Officer, President and Director | 42 | 42.68万美元 | 未持股 | 2022-12-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rich Russo, Jr. | 男 | Chief Executive Officer, President and Director | 42 | 42.68万美元 | 未持股 | 2022-12-07 |
| Daniel Gonsalves | 男 | Executive Vice President and Chief Financial Officer | 39 | 未披露 | 未持股 | 2022-12-07 |
董事简历
中英对照 | 中文 | 英文- Andre Auberton Herve
-
Andre Auberton Herve自2018年1月24日起担任公司董事会主席。Auberton-Herve先生是4A Consulting&Engineering的创始人，该公司为可再生能源和数字创新提供战略建议和咨询服务，并自2015年7月成立以来一直担任其总裁兼首席执行官。4A Consulting自2017年2月起向公司提供咨询服务，直到Auberton-Herve先生被任命为董事长。Auberton-Herve先生联合创立了Soitec SA，这是一家在Euronext Paris Stock Exchange上市的公司，设计和制造用于许多智能手机平台和计算活动的创新半导体材料，他曾担任总裁兼首席执行官（从1992年7月到2015年1月），以及荣誉董事长（2015年9月以来）。在Soitec SA时，Auberton-Herve先生负责监督公司的战略、运营和财务活动。他在十个国家建立了一个国际高科技集团，在欧洲、亚洲和美国建立了五个制造工厂。Auberton-Herve先生还领导该公司于1999年在Euronext上市，从那时起在一些世界上最大的投资银行筹集了大量资本。他被提名为法国荣誉军团骑士和功勋勋章骑士。
Andre Auberton Herve has been the Chairman of the Company's Board of Directors since January 24, 2018. Mr. Auberton Herve is the founder of 4A Consulting & Engineering, which provides strategic advice and consulting services with respect to renewable energy and digital innovation and has served as its President and CEO since its founding in July 2015. 4A Consulting provided consulting services to the Company from February 2017 until Mr. Auberton-Herve's appointment as Chairman. Mr. Auberton Herve co-founded Soitec SA, a publicly traded company on the Euronext Paris stock exchange which designs and manufactures innovative semiconductor materials which are Bionik Laboratories Corp. ed in many smartphone platforms and computing activities, where he was President and CEO from July 1992 until January 2015, then Chairman and Chairman Emeritus since September 2015. While at Soitec SA, Mr. Auberton Herve was responsible for overseeing the strategic, operational and financial activities of the company. He built an international high-tech group in ten countries and five manufacturing facilities in Europe, Asia and the U.S. Mr. Auberton Herve also led the company through its listing on Euronext in 1999, raising significant amounts of capital since then with some of the world's largest investment banks. He has been nominated Knight of the Legion of Honor and Knight of the Order of Merit in France. Mr. Auberton Herve holds a Doctorate degree in Semiconductor Physics and a Master's degree in Materials Science from Ecole Centrale de Lyon in France. - Andre Auberton Herve自2018年1月24日起担任公司董事会主席。Auberton-Herve先生是4A Consulting&Engineering的创始人，该公司为可再生能源和数字创新提供战略建议和咨询服务，并自2015年7月成立以来一直担任其总裁兼首席执行官。4A Consulting自2017年2月起向公司提供咨询服务，直到Auberton-Herve先生被任命为董事长。Auberton-Herve先生联合创立了Soitec SA，这是一家在Euronext Paris Stock Exchange上市的公司，设计和制造用于许多智能手机平台和计算活动的创新半导体材料，他曾担任总裁兼首席执行官（从1992年7月到2015年1月），以及荣誉董事长（2015年9月以来）。在Soitec SA时，Auberton-Herve先生负责监督公司的战略、运营和财务活动。他在十个国家建立了一个国际高科技集团，在欧洲、亚洲和美国建立了五个制造工厂。Auberton-Herve先生还领导该公司于1999年在Euronext上市，从那时起在一些世界上最大的投资银行筹集了大量资本。他被提名为法国荣誉军团骑士和功勋勋章骑士。
- Andre Auberton Herve has been the Chairman of the Company's Board of Directors since January 24, 2018. Mr. Auberton Herve is the founder of 4A Consulting & Engineering, which provides strategic advice and consulting services with respect to renewable energy and digital innovation and has served as its President and CEO since its founding in July 2015. 4A Consulting provided consulting services to the Company from February 2017 until Mr. Auberton-Herve's appointment as Chairman. Mr. Auberton Herve co-founded Soitec SA, a publicly traded company on the Euronext Paris stock exchange which designs and manufactures innovative semiconductor materials which are Bionik Laboratories Corp. ed in many smartphone platforms and computing activities, where he was President and CEO from July 1992 until January 2015, then Chairman and Chairman Emeritus since September 2015. While at Soitec SA, Mr. Auberton Herve was responsible for overseeing the strategic, operational and financial activities of the company. He built an international high-tech group in ten countries and five manufacturing facilities in Europe, Asia and the U.S. Mr. Auberton Herve also led the company through its listing on Euronext in 1999, raising significant amounts of capital since then with some of the world's largest investment banks. He has been nominated Knight of the Legion of Honor and Knight of the Order of Merit in France. Mr. Auberton Herve holds a Doctorate degree in Semiconductor Physics and a Master's degree in Materials Science from Ecole Centrale de Lyon in France.
- Michal Prywata
-
Michal Prywata是Bionik Canada的联合创始人，自2017年6月起担任首席技术官，自2013年4月至2017年6月担任首席运营官，自2011年3月起担任董事。2011年3月至2013年4月，Prywata先生曾担任我们的首席执行官。Prywata先生在瑞尔森大学（Ryerson University）学习生物医学工程直到第二年结束，专注于医疗产品的电子和软件开发。他在赢得技术展示和发明解决重大未满足需求和未开发市场的技术方面有着良好的记录。他曾任职Bionik Canada公司5年，管理技术进步、管理日常运营，并将概念开发成产品。此外，Prywata先生与他的联合创始人和Bloch先生一起负责筹集和确保初始种子资本以及随后的资本筹集。Prywata先生是公司ARKE技术平台的共同发明人。Prywata先生担任董事会成员，因为他是公司的创始人和他目前在公司的执行职位。
Michal Prywata is the co-founder of Bionik Canada and served as Bionik's Chief Technology Officer from June 2017 to April 2021, Chief Operating Officer from April 2013 to June 2017, as a director from March 2011 to September 2018, and again since March 2019. Mr. Prywata previously served as Bionik Laboratories Corp. Chief Executive Officer from March 2011 to April 2013. Mr. Prywata studied biomedical engineering at Ryerson University until the end of his second year, with a focus on electronics and software development for medical products. He has a track record of winning technology showcases and inventing technologies that address significant unmet needs and untapped markets. He had spent the past five years with Bionik Canada, managing technological advancements, managing day-to-day operations, and developing concepts into products. In addition, Mr. Prywata, together with the Company's other co-founder and its former CEO, was responsible for raising and securing initial seed capital and subsequent capital raises. Mr. Prywata is the co-inventor of the Company's ARKE technology platform. Mr. Prywata serves as a member of the Board of Directors due to his being a founder of the Company. - Michal Prywata是Bionik Canada的联合创始人，自2017年6月起担任首席技术官，自2013年4月至2017年6月担任首席运营官，自2011年3月起担任董事。2011年3月至2013年4月，Prywata先生曾担任我们的首席执行官。Prywata先生在瑞尔森大学（Ryerson University）学习生物医学工程直到第二年结束，专注于医疗产品的电子和软件开发。他在赢得技术展示和发明解决重大未满足需求和未开发市场的技术方面有着良好的记录。他曾任职Bionik Canada公司5年，管理技术进步、管理日常运营，并将概念开发成产品。此外，Prywata先生与他的联合创始人和Bloch先生一起负责筹集和确保初始种子资本以及随后的资本筹集。Prywata先生是公司ARKE技术平台的共同发明人。Prywata先生担任董事会成员，因为他是公司的创始人和他目前在公司的执行职位。
- Michal Prywata is the co-founder of Bionik Canada and served as Bionik's Chief Technology Officer from June 2017 to April 2021, Chief Operating Officer from April 2013 to June 2017, as a director from March 2011 to September 2018, and again since March 2019. Mr. Prywata previously served as Bionik Laboratories Corp. Chief Executive Officer from March 2011 to April 2013. Mr. Prywata studied biomedical engineering at Ryerson University until the end of his second year, with a focus on electronics and software development for medical products. He has a track record of winning technology showcases and inventing technologies that address significant unmet needs and untapped markets. He had spent the past five years with Bionik Canada, managing technological advancements, managing day-to-day operations, and developing concepts into products. In addition, Mr. Prywata, together with the Company's other co-founder and its former CEO, was responsible for raising and securing initial seed capital and subsequent capital raises. Mr. Prywata is the co-inventor of the Company's ARKE technology platform. Mr. Prywata serves as a member of the Board of Directors due to his being a founder of the Company.
- Remi Gaston Dreyfus
-
Remi Gaston Dreyfus自2017年9月1日起担任公司董事。自2007年以来，Gaston-Dreyfus先生一直担任巴黎RGD Investssements S.A.S.的首席执行官兼创始人，该公司是巴黎房地产资产的开发商和投资者。在2007年之前，Gaston-Dreyfus先生是摄影新闻集团A.G.I.的股东，董事长兼首席执行官，包括Gamma Press Agency。Gaston-Dreyfus先生在1984年是一家巴黎律师事务所的联合创始人，直到1992年是一名法国律师。
Remi Gaston Dreyfus has been a director of the Company since September 1, 2017. Since 2007, Mr. Gaston-Dreyfus has been the CEO and Founder of GDG Investissements S.A.S. in Paris, a developer of and investor in real estate assets in Paris. Prior to 2007, Mr. Gaston-Dreyfus was a shareholder, Chairman and CEO of the Photo-Journalism group A.G.I. (including Gamma Press Agency). Mr. Gaston-Dreyfus was a co-founder of a Parisian law firm in 1984 and was a French lawyer until 1992. - Remi Gaston Dreyfus自2017年9月1日起担任公司董事。自2007年以来，Gaston-Dreyfus先生一直担任巴黎RGD Investssements S.A.S.的首席执行官兼创始人，该公司是巴黎房地产资产的开发商和投资者。在2007年之前，Gaston-Dreyfus先生是摄影新闻集团A.G.I.的股东，董事长兼首席执行官，包括Gamma Press Agency。Gaston-Dreyfus先生在1984年是一家巴黎律师事务所的联合创始人，直到1992年是一名法国律师。
- Remi Gaston Dreyfus has been a director of the Company since September 1, 2017. Since 2007, Mr. Gaston-Dreyfus has been the CEO and Founder of GDG Investissements S.A.S. in Paris, a developer of and investor in real estate assets in Paris. Prior to 2007, Mr. Gaston-Dreyfus was a shareholder, Chairman and CEO of the Photo-Journalism group A.G.I. (including Gamma Press Agency). Mr. Gaston-Dreyfus was a co-founder of a Parisian law firm in 1984 and was a French lawyer until 1992.
- Joseph Martin
-
Joseph Martin自2017年以来一直担任我们的董事会成员。Martin先生自2001年以来一直是Brooks Automation的董事会成员，并自2006年以来一直担任董事会主席。自2018年以来，马丁先生一直担任全球梦百合公司Bionik Labs的董事会成员。Martin先生还担任Collectors Universe的董事会成员，该公司是一家公开交易的公司，为硬币，交易卡，活动门票，签名，体育和历史纪念品的交易商和收藏家提供认证和分级服务。在2006年退休之前，马丁先生是Fairchild SemiconductorInternational，Inc.的联合主席，也是该公司董事会的副主席。从2004年到2017年，马丁先生还担任Soitec的董事会成员，Soitec是一家总部位于法国的上市公司，设计和制造创新的半导体材料。Martin先生还任职于Embry-Riddle Aeronautical University的董事会。马丁先生于1974年获得航空学士学位，并于2018年获得Emry-Riddle Aeronautical University的荣誉博士学位。Martin先生于1976年获得缅因大学（University of Maine）的工商管理硕士学位。Martin先生持有美国公司董事学院（American College of Corporate Directors）的执行硕士专业认证，这是一家董事教育和认证组织。
Joseph Martin,has served as a member of Allegro Microsystems, Inc. Board since 2017. Since 2001, Mr. Martin has been a member of the board of directors of Azenta Inc., which changed its name from Brooks Automation in December 2021, and has been Chairman since 2006. Mr. Martin has also served on the board of directors of Bionik Labs since 2018. Previously, he served as Co-Chairman of Fairchild Semiconductor Corporation, and prior to that as its Senior Executive Vice President and Chief Financial Officer. He also served as the Vice Chairman of Fairchild's board of directors. Mr. Martin has also previously served on the board of directors of other public companies, including Collectors Universe (chair of the Nominating and Governance Committee), Soitec Semiconductor (chair of the Audit Committee), and ChipPac Inc. (chair of the Audit Committee). Mr. Martin also serves on the board of trustees of Embry-Riddle Aeronautical University. Mr. Martin received a B.S. in Aeronautics in 1974 and was awarded an honorary Ph.D. in 2018, both from Embry-Riddle Aeronautical University. Mr. Martin received an M.B.A. from the University of Maine in 1976. Mr. Martin holds an Executive Master's Professional Certification from the American College of Corporate Directors, a director education and credentialing organization, and he is also a member of the National Association of Corporate Directors. - Joseph Martin自2017年以来一直担任我们的董事会成员。Martin先生自2001年以来一直是Brooks Automation的董事会成员，并自2006年以来一直担任董事会主席。自2018年以来，马丁先生一直担任全球梦百合公司Bionik Labs的董事会成员。Martin先生还担任Collectors Universe的董事会成员，该公司是一家公开交易的公司，为硬币，交易卡，活动门票，签名，体育和历史纪念品的交易商和收藏家提供认证和分级服务。在2006年退休之前，马丁先生是Fairchild SemiconductorInternational，Inc.的联合主席，也是该公司董事会的副主席。从2004年到2017年，马丁先生还担任Soitec的董事会成员，Soitec是一家总部位于法国的上市公司，设计和制造创新的半导体材料。Martin先生还任职于Embry-Riddle Aeronautical University的董事会。马丁先生于1974年获得航空学士学位，并于2018年获得Emry-Riddle Aeronautical University的荣誉博士学位。Martin先生于1976年获得缅因大学（University of Maine）的工商管理硕士学位。Martin先生持有美国公司董事学院（American College of Corporate Directors）的执行硕士专业认证，这是一家董事教育和认证组织。
- Joseph Martin,has served as a member of Allegro Microsystems, Inc. Board since 2017. Since 2001, Mr. Martin has been a member of the board of directors of Azenta Inc., which changed its name from Brooks Automation in December 2021, and has been Chairman since 2006. Mr. Martin has also served on the board of directors of Bionik Labs since 2018. Previously, he served as Co-Chairman of Fairchild Semiconductor Corporation, and prior to that as its Senior Executive Vice President and Chief Financial Officer. He also served as the Vice Chairman of Fairchild's board of directors. Mr. Martin has also previously served on the board of directors of other public companies, including Collectors Universe (chair of the Nominating and Governance Committee), Soitec Semiconductor (chair of the Audit Committee), and ChipPac Inc. (chair of the Audit Committee). Mr. Martin also serves on the board of trustees of Embry-Riddle Aeronautical University. Mr. Martin received a B.S. in Aeronautics in 1974 and was awarded an honorary Ph.D. in 2018, both from Embry-Riddle Aeronautical University. Mr. Martin received an M.B.A. from the University of Maine in 1976. Mr. Martin holds an Executive Master's Professional Certification from the American College of Corporate Directors, a director education and credentialing organization, and he is also a member of the National Association of Corporate Directors.
- Charles Matine
-
Charles Matine自2018年2月起担任ENLAPS（一家为摄影师提供延时解决方案的初创公司）的顾问委员会成员。Matine先生自2015年7月起担任C4Ventures（总部位于伦敦的风险基金，支持媒体，电子商务和硬件初创公司）的战略顾问。Matine先生于2014年4月创立了B&Associates，这是一家营销和数字转型咨询公司，并自2014年4月起担任其首席执行官。在此之前，Matine先生于2010年7月至2014年4月担任Apple France的业务部门总监，领导教育和研究业务部门，从2006年4月到2010年6月，他曾担任Apple Europe公司的高级营销经理，在那里他负责推广Apple产品，并定义中欧、中东和非洲的营销、公关和品牌策略。任职Apple公司之前，Matine先生曾广泛从事营销和广告工作，在整个欧洲推广技术产品和品牌。Matine先生曾在Sciences PO the Paris Institute for Political Studies公共服务部学习，并持有IFA-Sciences PO非执行董事证书。
Charles Matine serves as an Advisory Board Member of Enlaps, a start-up company providing a time-lapse solution to photographers, since February 2018. Since July 2015, Mr. Matine has served as a strategic advisor to C4 Ventures, a London-based venture fund supporting media, e-commerce and hardware startups. In April 2014, Mr. Matine founded B & Associates, a marketing and digital transformation consultancy firm, and has served as its CEO since April 2014. Prior to that, Mr. Matine served as a Business Unit Director of Apple France from July 2010 to April 2014, where he led the Education and Research business unit, and as a Senior Marketing Manager of Apple Europe from April 2006 to June 2010, where he was responsible for promoting Apple products and defining marketing, PR and branding strategies within central Europe, the Middle East and Africa. Prior to Apple, Mr. Matine worked extensively in marketing and advertising, promoting technology products and brands throughout Europe. Mr. Matine studied at Sciences Po (the Paris Institute for Political Studies, Section Public Service) and holds the IFA-Sciences Po non-executive director certificate. - Charles Matine自2018年2月起担任ENLAPS（一家为摄影师提供延时解决方案的初创公司）的顾问委员会成员。Matine先生自2015年7月起担任C4Ventures（总部位于伦敦的风险基金，支持媒体，电子商务和硬件初创公司）的战略顾问。Matine先生于2014年4月创立了B&Associates，这是一家营销和数字转型咨询公司，并自2014年4月起担任其首席执行官。在此之前，Matine先生于2010年7月至2014年4月担任Apple France的业务部门总监，领导教育和研究业务部门，从2006年4月到2010年6月，他曾担任Apple Europe公司的高级营销经理，在那里他负责推广Apple产品，并定义中欧、中东和非洲的营销、公关和品牌策略。任职Apple公司之前，Matine先生曾广泛从事营销和广告工作，在整个欧洲推广技术产品和品牌。Matine先生曾在Sciences PO the Paris Institute for Political Studies公共服务部学习，并持有IFA-Sciences PO非执行董事证书。
- Charles Matine serves as an Advisory Board Member of Enlaps, a start-up company providing a time-lapse solution to photographers, since February 2018. Since July 2015, Mr. Matine has served as a strategic advisor to C4 Ventures, a London-based venture fund supporting media, e-commerce and hardware startups. In April 2014, Mr. Matine founded B & Associates, a marketing and digital transformation consultancy firm, and has served as its CEO since April 2014. Prior to that, Mr. Matine served as a Business Unit Director of Apple France from July 2010 to April 2014, where he led the Education and Research business unit, and as a Senior Marketing Manager of Apple Europe from April 2006 to June 2010, where he was responsible for promoting Apple products and defining marketing, PR and branding strategies within central Europe, the Middle East and Africa. Prior to Apple, Mr. Matine worked extensively in marketing and advertising, promoting technology products and brands throughout Europe. Mr. Matine studied at Sciences Po (the Paris Institute for Political Studies, Section Public Service) and holds the IFA-Sciences Po non-executive director certificate.
- Audrey Thevenon
-
Audrey Thevenon是美国国家科学、工程和医学研究院（National Academies of Sciences，Engineering and Medicine”；）生命科学委员会的项目官员，该机构是一家私人非营利机构，为科学、工程和健康事务提供高质量、客观的建议，自2016年10月以来，曾于2014年8月至2016年10月担任NASEM的副项目官。Thevenon博士还担任NASEM实验室动物研究期刊研究所（Journal Institute for Laboratory Animal Research）的主编。2012年2月至2014年7月，Thevenon博士是马萨诸塞州贝塞斯达the Uniformed Services University of the Health Sciences的博士后。Thevenon博士还在夏威夷大学（University of Hawaii）完成胎盘药理学博士后奖学金。Thevenon博士在乔治敦大学（Georgetown University）获得生物学博士学位和硕士学位，并在法国雷恩大学（University of Rennes1）获得细胞生物学与生理学硕士学位以及生命科学与环境学士学位。
Audrey Thevenon serves as a Senior Program Officer on the Board of Life Sciences at the National Academies of Sciences, Engineering and Medicine ("NASEM"), a private, nonprofit institution that provides high-quality, objective advice on science, engineering, and health matters. Since she joined NASEM in 2014, Dr. Thévenon supports collaborative regional and international activities at the intersection of infectious disease research and policy decision intended explicitly at promoting transdisciplinary research in global health. From February 2012 to July 2014, Dr. Thévenon was a Postdoctoral Fellow at the Uniformed Services University of the Health Sciences in Bethesda, MD. Dr. Thévenon has also completed a Postdoctoral Fellowship at the University of Hawaii in placental pharmacology. Dr. Thévenon has a Ph.D. and an MS both in Biology from Georgetown University, as well as an MS in Cell Biology & Physiology and a BS in Life Sciences and Environment from the University of Rennes 1 in France. - Audrey Thevenon是美国国家科学、工程和医学研究院（National Academies of Sciences，Engineering and Medicine”；）生命科学委员会的项目官员，该机构是一家私人非营利机构，为科学、工程和健康事务提供高质量、客观的建议，自2016年10月以来，曾于2014年8月至2016年10月担任NASEM的副项目官。Thevenon博士还担任NASEM实验室动物研究期刊研究所（Journal Institute for Laboratory Animal Research）的主编。2012年2月至2014年7月，Thevenon博士是马萨诸塞州贝塞斯达the Uniformed Services University of the Health Sciences的博士后。Thevenon博士还在夏威夷大学（University of Hawaii）完成胎盘药理学博士后奖学金。Thevenon博士在乔治敦大学（Georgetown University）获得生物学博士学位和硕士学位，并在法国雷恩大学（University of Rennes1）获得细胞生物学与生理学硕士学位以及生命科学与环境学士学位。
- Audrey Thevenon serves as a Senior Program Officer on the Board of Life Sciences at the National Academies of Sciences, Engineering and Medicine ("NASEM"), a private, nonprofit institution that provides high-quality, objective advice on science, engineering, and health matters. Since she joined NASEM in 2014, Dr. Thévenon supports collaborative regional and international activities at the intersection of infectious disease research and policy decision intended explicitly at promoting transdisciplinary research in global health. From February 2012 to July 2014, Dr. Thévenon was a Postdoctoral Fellow at the Uniformed Services University of the Health Sciences in Bethesda, MD. Dr. Thévenon has also completed a Postdoctoral Fellowship at the University of Hawaii in placental pharmacology. Dr. Thévenon has a Ph.D. and an MS both in Biology from Georgetown University, as well as an MS in Cell Biology & Physiology and a BS in Life Sciences and Environment from the University of Rennes 1 in France.
- Rich Russo, Jr.
-
Rich Russo，Jr.自2020年11月起担任公司首席财务官，自2021年7月起担任临时首席执行官。他拥有超过15年的财务和会计领导经验，并拥有注册会计师。从2017年至2020年，Russo，Jr.先生担任iCarbonx的财务副总裁兼美国首席财务官，负责3家公司的合并，筹款和美国公司的最终解散。从2007年到2016年，Russo，Jr.先生在生命科学，制药和医疗器械行业的纳斯达克上市公司担任过各种关键领导职务。Russo Jr.曾担任Pieris制药公司（临床阶段生物技术公司）、Juniper Pharmaceuticals（女性健康公司，专注于开发疗法）和Cynosure（医疗设备公司，专注于美容治疗系统）的公司财务总监。在这些职位中，Russo，Jr.先生负责所有财务活动和SEC报告，包括与业务负责人密切合作，以确保整个组织有效和高效的财务程序。他的职业生涯始于2005年，在那里他曾担任Pricewaterhouse Coopers公司的保证集团的审计师。
Rich Russo, Jr. has served as Bionik Laboratories Corp. President and Chief Executive Officer, and as a member of Bionik Laboratories Corp. Board of Directors, since October 2022. Prior to that, he served as the Company's Chief Financial Officer since November 2020 and the Interim Chief Executive Officer since July 2021. He has over 20 years of finance and accounting leadership experience and holds a CPA. From 2017-2020, Mr. Russo served as Vice President of Finance and U.S. Chief Financial Officer of ICarbonX, where he was responsible for the merger of 3 companies, fundraising, and the ultimate dissolution of the U.S. companies. From 2007-2016, Mr. Russo held various key leadership roles for NASDAQ listed companies in life sciences, pharmaceutical and medical device industries. Mr. Russo served as Corporate Controller for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, Juniper Pharmaceuticals, a woman's health company focused on developing therapeutics and Cynosure, a medical device company focused on aesthetic treatment systems. In each of these roles, Mr. Russo was responsible for all finance activities and SEC reporting along including partnering closely with the business leaders to ensure effective and efficient financial procedures throughout the organization. Mr. Russo started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group. - Rich Russo，Jr.自2020年11月起担任公司首席财务官，自2021年7月起担任临时首席执行官。他拥有超过15年的财务和会计领导经验，并拥有注册会计师。从2017年至2020年，Russo，Jr.先生担任iCarbonx的财务副总裁兼美国首席财务官，负责3家公司的合并，筹款和美国公司的最终解散。从2007年到2016年，Russo，Jr.先生在生命科学，制药和医疗器械行业的纳斯达克上市公司担任过各种关键领导职务。Russo Jr.曾担任Pieris制药公司（临床阶段生物技术公司）、Juniper Pharmaceuticals（女性健康公司，专注于开发疗法）和Cynosure（医疗设备公司，专注于美容治疗系统）的公司财务总监。在这些职位中，Russo，Jr.先生负责所有财务活动和SEC报告，包括与业务负责人密切合作，以确保整个组织有效和高效的财务程序。他的职业生涯始于2005年，在那里他曾担任Pricewaterhouse Coopers公司的保证集团的审计师。
- Rich Russo, Jr. has served as Bionik Laboratories Corp. President and Chief Executive Officer, and as a member of Bionik Laboratories Corp. Board of Directors, since October 2022. Prior to that, he served as the Company's Chief Financial Officer since November 2020 and the Interim Chief Executive Officer since July 2021. He has over 20 years of finance and accounting leadership experience and holds a CPA. From 2017-2020, Mr. Russo served as Vice President of Finance and U.S. Chief Financial Officer of ICarbonX, where he was responsible for the merger of 3 companies, fundraising, and the ultimate dissolution of the U.S. companies. From 2007-2016, Mr. Russo held various key leadership roles for NASDAQ listed companies in life sciences, pharmaceutical and medical device industries. Mr. Russo served as Corporate Controller for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, Juniper Pharmaceuticals, a woman's health company focused on developing therapeutics and Cynosure, a medical device company focused on aesthetic treatment systems. In each of these roles, Mr. Russo was responsible for all finance activities and SEC reporting along including partnering closely with the business leaders to ensure effective and efficient financial procedures throughout the organization. Mr. Russo started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group.
高管简历
中英对照 | 中文 | 英文- Rich Russo, Jr.
Rich Russo，Jr.自2020年11月起担任公司首席财务官，自2021年7月起担任临时首席执行官。他拥有超过15年的财务和会计领导经验，并拥有注册会计师。从2017年至2020年，Russo，Jr.先生担任iCarbonx的财务副总裁兼美国首席财务官，负责3家公司的合并，筹款和美国公司的最终解散。从2007年到2016年，Russo，Jr.先生在生命科学，制药和医疗器械行业的纳斯达克上市公司担任过各种关键领导职务。Russo Jr.曾担任Pieris制药公司（临床阶段生物技术公司）、Juniper Pharmaceuticals（女性健康公司，专注于开发疗法）和Cynosure（医疗设备公司，专注于美容治疗系统）的公司财务总监。在这些职位中，Russo，Jr.先生负责所有财务活动和SEC报告，包括与业务负责人密切合作，以确保整个组织有效和高效的财务程序。他的职业生涯始于2005年，在那里他曾担任Pricewaterhouse Coopers公司的保证集团的审计师。
Rich Russo, Jr. has served as Bionik Laboratories Corp. President and Chief Executive Officer, and as a member of Bionik Laboratories Corp. Board of Directors, since October 2022. Prior to that, he served as the Company's Chief Financial Officer since November 2020 and the Interim Chief Executive Officer since July 2021. He has over 20 years of finance and accounting leadership experience and holds a CPA. From 2017-2020, Mr. Russo served as Vice President of Finance and U.S. Chief Financial Officer of ICarbonX, where he was responsible for the merger of 3 companies, fundraising, and the ultimate dissolution of the U.S. companies. From 2007-2016, Mr. Russo held various key leadership roles for NASDAQ listed companies in life sciences, pharmaceutical and medical device industries. Mr. Russo served as Corporate Controller for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, Juniper Pharmaceuticals, a woman's health company focused on developing therapeutics and Cynosure, a medical device company focused on aesthetic treatment systems. In each of these roles, Mr. Russo was responsible for all finance activities and SEC reporting along including partnering closely with the business leaders to ensure effective and efficient financial procedures throughout the organization. Mr. Russo started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group.- Rich Russo，Jr.自2020年11月起担任公司首席财务官，自2021年7月起担任临时首席执行官。他拥有超过15年的财务和会计领导经验，并拥有注册会计师。从2017年至2020年，Russo，Jr.先生担任iCarbonx的财务副总裁兼美国首席财务官，负责3家公司的合并，筹款和美国公司的最终解散。从2007年到2016年，Russo，Jr.先生在生命科学，制药和医疗器械行业的纳斯达克上市公司担任过各种关键领导职务。Russo Jr.曾担任Pieris制药公司（临床阶段生物技术公司）、Juniper Pharmaceuticals（女性健康公司，专注于开发疗法）和Cynosure（医疗设备公司，专注于美容治疗系统）的公司财务总监。在这些职位中，Russo，Jr.先生负责所有财务活动和SEC报告，包括与业务负责人密切合作，以确保整个组织有效和高效的财务程序。他的职业生涯始于2005年，在那里他曾担任Pricewaterhouse Coopers公司的保证集团的审计师。
- Rich Russo, Jr. has served as Bionik Laboratories Corp. President and Chief Executive Officer, and as a member of Bionik Laboratories Corp. Board of Directors, since October 2022. Prior to that, he served as the Company's Chief Financial Officer since November 2020 and the Interim Chief Executive Officer since July 2021. He has over 20 years of finance and accounting leadership experience and holds a CPA. From 2017-2020, Mr. Russo served as Vice President of Finance and U.S. Chief Financial Officer of ICarbonX, where he was responsible for the merger of 3 companies, fundraising, and the ultimate dissolution of the U.S. companies. From 2007-2016, Mr. Russo held various key leadership roles for NASDAQ listed companies in life sciences, pharmaceutical and medical device industries. Mr. Russo served as Corporate Controller for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, Juniper Pharmaceuticals, a woman's health company focused on developing therapeutics and Cynosure, a medical device company focused on aesthetic treatment systems. In each of these roles, Mr. Russo was responsible for all finance activities and SEC reporting along including partnering closely with the business leaders to ensure effective and efficient financial procedures throughout the organization. Mr. Russo started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group.
- Daniel Gonsalves
Daniel Gonsalves自2022年10月起担任Bionik Laboratories Corp.执行副总裁兼Chief Financial Officer。在此之前，2021年9月起担任Bionik Laboratories Corp.的公司财务总监。Gonsalves先生拥有超过15年的财务和会计领导经验，是一名注册会计师。2017年6月至2021年9月，他在Destination XL Group, Inc.（纳斯达克股票代码：DXLG）担任过多个职务，包括财务规划与分析总监（2018年11月-2021年9月）和财务会计与报告总监（2017年6月-2018年11月）。2014年2月至2017年6月，Gonsalves先生担任Corporate Finance Group Inc.的高级经理，该公司是一家财务和会计咨询公司，为医疗设备、制药、技术和软件行业的客户提供服务。Gonsalves先生的职业生涯始于2005年，他在德勤的保证小组担任审计员。Gonsalves先生毕业于罗德岛州普罗维登斯的普罗维登斯学院，并获得会计学学士学位。
Daniel Gonsalves has been Bionik Laboratories Corp. Executive Vice President and Chief Financial Officer since October 2022. Prior to that, from September 2021, he was Bionik Laboratories Corp. Corporate Controller. Mr. Gonsalves has over 15 years of finance and accounting leadership experience and is a Certified Public Accountant. From June 2017 to September 2021, he had various roles at Destination XL Group, Inc. (Nasdaq:DXLG), a publicly-traded men's retail company including as Director of Financial Planning & Analysis (November 2018-September 2021) and as Director of Financial Accounting & Reporting (June 2017-November 2018). From February 2014 to June 2017, Mr. Gonsalves was a Senior Manager at Corporate Finance Group Inc., a finance and accounting consulting firm where he served clients throughout the medical device, pharmaceutical, technology and software industries. Mr. Gonsalves started his career in 2005, where he served as an auditor at Deloitte in the assurance group. Mr. Gonsalves is a graduate of Providence College in Providence, RI, where he graduated with a Bachelor of Science in Accounting.- Daniel Gonsalves自2022年10月起担任Bionik Laboratories Corp.执行副总裁兼Chief Financial Officer。在此之前，2021年9月起担任Bionik Laboratories Corp.的公司财务总监。Gonsalves先生拥有超过15年的财务和会计领导经验，是一名注册会计师。2017年6月至2021年9月，他在Destination XL Group, Inc.（纳斯达克股票代码：DXLG）担任过多个职务，包括财务规划与分析总监（2018年11月-2021年9月）和财务会计与报告总监（2017年6月-2018年11月）。2014年2月至2017年6月，Gonsalves先生担任Corporate Finance Group Inc.的高级经理，该公司是一家财务和会计咨询公司，为医疗设备、制药、技术和软件行业的客户提供服务。Gonsalves先生的职业生涯始于2005年，他在德勤的保证小组担任审计员。Gonsalves先生毕业于罗德岛州普罗维登斯的普罗维登斯学院，并获得会计学学士学位。
- Daniel Gonsalves has been Bionik Laboratories Corp. Executive Vice President and Chief Financial Officer since October 2022. Prior to that, from September 2021, he was Bionik Laboratories Corp. Corporate Controller. Mr. Gonsalves has over 15 years of finance and accounting leadership experience and is a Certified Public Accountant. From June 2017 to September 2021, he had various roles at Destination XL Group, Inc. (Nasdaq:DXLG), a publicly-traded men's retail company including as Director of Financial Planning & Analysis (November 2018-September 2021) and as Director of Financial Accounting & Reporting (June 2017-November 2018). From February 2014 to June 2017, Mr. Gonsalves was a Senior Manager at Corporate Finance Group Inc., a finance and accounting consulting firm where he served clients throughout the medical device, pharmaceutical, technology and software industries. Mr. Gonsalves started his career in 2005, where he served as an auditor at Deloitte in the assurance group. Mr. Gonsalves is a graduate of Providence College in Providence, RI, where he graduated with a Bachelor of Science in Accounting.